BioSpace News Archive

NetworkNewsAudio – Lexaria Bioscience Corp. announces the availability of a broadcast titled, “The Power of Science to Stop a Killer.”.

Eli Lilly and Company (NYSE: LLY) today announced the upcoming retirement of one executive committee member, the naming of his successor, and the hiring of a new chief commercial officer for Loxo@Lilly.

Panbela Therapeutics, Inc. announced it has enrolled the first patient in its global clinical trial to study SBP-101 in combination with Gemcitabine and Nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma, which is referred to as the ASPIRE trial, a randomized double-blind placebo-controlled trial, with a primary endpoint of overall survival.

Ceapro Inc. (TSX-V: CZO; OTCQX:CRPOF) (“Ceapro” or the “Company”), a growth-stage biotechnology company focused on the development and commercialization of active ingredients for healthcare and cosmetic industries, announced it has entered into an additional research project expanding on the ongoing collaboration with McMaster University to develop an inhalable immuno-therapeutic/-prophylactic for COVID-19-induced lung fibrosis.

Viracta Therapeutics, Inc. (Nasdaq: VIRX), a precision oncology company targeting virus-associated malignancies, today announced the appointment of Jane Chung, R.Ph., as an independent member to its Board of Directors.

Todos Medical, Ltd. (OTCQB: TOMDF), a comprehensive medical diagnostics and related solutions company, today announced that its majority-owned subsidiary 3CL Pharma, Ltd has finalized plans for a proposed safety and efficacy clinical trial for its 3CL protease inhibitor immune support dietary supplement Tollovid™ in patients with Long COVID.

Fact.MR – A Market Research and Competitive Intelligence Provider: The global OTC analgesics market was valued at US $ 25 Billion in 2020, and is expected to accelerate at a CAGR of 5% through 2031.

Valneva SE, a specialty vaccine company, reported consolidated financial results for the first half of the year, ended June 30, 2022.

Wilmington, Delaware, United States, Transparency Market Research Inc. – The penetration of healthcare IT in patient care has underpinned the steady evolution of patient engagement with the health systems world over.

Other non-operating result of € (89.8) m (H1 2021: € 106.1 m) explained by the non-cash fair value adjustments of the equity investment in publicly listed Exscientia plc.